Genmab (GMAB)

Copenhagen
Currency in DKK
Disclaimer
2,604.0
-54.0
(-2.03%)
Closed
Day's Range
2,596.0
2,655.0
52 wk Range
1,863.0
3,327.0
Volume
118,772
Prev. Close
2,658
Open
2,655
Day's Range
2,596-2,655
52 wk Range
1,863-3,327
Volume
118,772
Average Vol. (3m)
104,865
1-Year Change
12.82%
Shares Outstanding
65,361,690
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Daily
Weekly
Monthly
More

Genmab News

Genmab Analysis

Genmab Company Profile

Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

Employees
1445
Market
Denmark